Current research and treatment for gastrointestinal stromal tumors

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract and have gained considerable research and treat-ment interest, especially in the last two decades.GISTs are driven by mutations commonly found in the KIT gene and less commonly in the platelet-derived growth factor receptor alpha gene, BRAF gene and succinate dehydrogenase gene.GISTs behave in a spectrum of malignant potential, and both the tumor size and mitotic index are the most commonly used prognostic criteria.Whilst surgical resection can offer the best cure, targeted therapy in the form of tyrosine kinase inhibitors (TKIs) has revolutionized the management options.As the first-line TKI, imatinib offers treatment for advanced and metastatic GISTs, adjuvant therapy in high-risk GISTs and as a neoadjuvant agent to downsize large tumors prior to resection.The emergence of drug resistance has altered some treatment options, including prolonging the first-line TKI from 1 to 3 years, increasing the dose of TKI or switching to second-line TKI.Other newer TKIs, such as sunitinib and regorafenib, may offer some treatment options for imatinib-resistant GISTs.New molecular targeted therapies are being evaluated, such as inhibitors of BRAF, heat shock protein 90, glutamine and mitogenactivated protein kinase signaling, as well as inhibitors of apoptosis proteins antagonist and even immunotherapy.This editorial review summarizes the recent research trials and potential treatment targets that may influence our future patient-specific management of GISTs.The current guidelines in GIST management from Europe, North America and Asia are highlighted.